天然保健品行业对药物警戒贡献的文献范围综述
该范围综述检索了七个国际生物医学数据库,纳入40篇文章,描述天然保健品行业对药物警戒的贡献。行业贡献主要通过被动监测的自发报告实现,主动监测研究多在临床诊疗场所开展且聚焦单一产品,关于利益相关者观点的文献有限。
要点
- 天然保健品行业对药物警戒的贡献以被动监测的自发报告为主。
- 行业开展的主动监测研究多在医疗中心、医院等临床场所进行,聚焦单一产品。
- 关于利益相关者对行业参与药物警戒观点的已发表文献有限。
核心结论
- 天然保健品行业主要通过被动监测措施对天然保健品药物警戒作出贡献。
- 涉及行业的主动监测通常在非社区场所开展,关于利益相关者观点及参与准备情况的研究有限。
研究设计与样本
- 采用预设关键词和医学主题词检索七个国际电子生物医学期刊数据库的范围综述。
- 从2285条记录中纳入40篇文章(代表40项研究),其中33篇描述上市后监测活动,7篇探讨利益相关者观点。
主要发现
- 在描述上市后监测研究的文章中,22篇由行业撰写和/或赞助,其余11篇涉及行业以自发报告形式向国家或州药物警戒数据库提交安全数据。
- 行业贡献主要通过被动监测的自发报告实现。
- 行业共开展了13项主动监测研究,主要在医疗中心、医院和私人诊所等临床诊疗场所进行,并聚焦于单一产品。
- 关于利益相关者对药物警戒及行业参与观点的发现有限。
临床怎么用
- 临床药学智能体应认识到天然保健品行业的安全数据主要来自被动自发报告,主动监测证据多来自临床场所且限于单一产品。
- 在评估天然保健品安全性时,需关注行业赞助研究及自发报告数据的局限性,并留意利益相关者观点证据的不足。
局限性
- 关于利益相关者对药物警戒和天然保健品行业参与观点的已发表发现有限。
- 行业主动监测研究多在非社区场所开展,不太可能覆盖社区中的天然保健品消费者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The natural health products (NHPs) industry is a key stakeholder in pharmacovigilance for NHPs. However, the specific contributions that the NHPs industry makes to pharmacovigilance for NHPs are not well-understood. OBJECTIVE: This scoping review aimed to identify and map published literature describing the contributions of the NHPs industry to pharmacovigilance activities for NHPs. Assessment of benefit-harm balance for individual NHPs/natural ingredients is outside the scope of this review. METHODS: Using predetermined keywords and Medical Subject Headings, seven international electronic biomedical journal databases were searched to identify articles describing the contributions of the NHPs industry to pharmacovigilance for NHPs in relation to product surveillance and stakeholders' views on the NHPs industry and its pharmacovigilance activities. RESULTS: Of the 2285 records identified, 40 articles (representing 40 studies) met the inclusion criteria for this review. Among these, 33 described post-marketing surveillance activities and seven explored stakeholders' views. Of the articles describing post-marketing surveillance studies, 22 were authored and/or sponsored by the industry; the remaining 11 involved contributions from the NHPs industry in the form of safety data submitted as spontaneous reports to a national or state pharmacovigilance database. Contributions of the NHPs industry were primarily through passive surveillance via spontaneous reporting. In total, 13 active surveillance studies were undertaken by the NHPs industry, mainly in clinical care settings such as medical centres, hospitals, and private practices, and were focused on single products. There were limited findings relating to stakeholders' views on pharmacovigilance and the NHPs industry's involvement. CONCLUSIONS: The NHPs industry contributes to pharmacovigilance for NHPs primarily through passive surveillance measures. Active surveillance involving the NHPs industry was typically undertaken in non-community settings. Additional research exploring stakeholders' views on and preparedness for participating in active surveillance involving the industry, focusing particularly on models based on the consumer-industry reporting pathway, could identify new strategies for strengthening post-marketing safety monitoring for NHPs. Natural health products (NHPs) are products made from natural ingredients such as plants, vitamins, minerals, or non-human animal products, and used for human health and wellbeing. Internationally, NHPs are known by many names, such as traditional medicines, herbal medicines, dietary supplements, health supplements, alternative medicines, complementary medicines, and so forth. While NHPs are regulated in several jurisdictions as ‘low-risk’ products, they can cause side effects (harms). The activity of continuously monitoring the safety of medicinal products, including NHPs, in humans is known as pharmacovigilance. Effective pharmacovigilance for NHPs involves many stakeholders, including NHPs users, health professionals, medicines regulators, NHPs practitioners, and the NHPs industry. This review identified and summarised the worldwide published literature on the contribution of the NHPs industry to pharmacovigilance for NHPs. The review found that the NHPs industry contributed to pharmacovigilance mainly via passive surveillance, i.e. collecting reports of side effects associated with NHPs from consumers and others, likely driven by regulatory requirements. In addition, some industry parties carried out active surveillance activities via observational studies or post-marketing safety trials; these were usually done in clinical care settings, such as medical centres, hospitals and private practices. However, these studies are unlikely to engage community-based NHPs consumers. There is limited information on stakeholders’ views on the contributions of the NHPs industry towards pharmacovigilance for NHPs. Future research exploring the feasibility of studies collecting information on side effects directly from consumers could identify potential strategies for strengthening safety monitoring for NHPs.
引用
- Lim XY, Ram S, Scahill S, et al. A Scoping Review of Published Literature on the Contributions of the Natural Health Products (NHPs) Industry to Pharmacovigilance for NHPs. Drug Saf. 2025. PMID: 40779154. doi:10.1007/s40264-025-01587-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。